![Sanne de Jongh](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Sanne de Jongh is currently the Director at ADCendo ApS.
She is also an Investment Manager at Gilde Healthcare Partners BV since 2019 and a Partner at Oxford Science Enterprises PLC since 2023.
Previously, she worked as an Analyst at Anterra Capital BV from 2014 to 2017.
Postes actifs de Sanne de Jongh
| Sociétés | Poste | Début |
|---|---|---|
Gilde Healthcare Partners BV
 Gilde Healthcare Partners BV Investment ManagersFinance Gilde Healthcare Partners invests in lower middle market companies located in North America and Europe with an EBITDA of EUR 3 -20 million. The firm targets companies operating across a broad range of sectors and industries. It provides financing for seed, early, later, buyout and growth stage capital requirements with an investment size of EUR 50 million. It takes both minority and majority positions. | Private Equity Investor | 01/01/2019 |
ADCendo ApS
 ADCendo ApS BiotechnologyHealth Technology Operates as a clinical-stage biotech company that dedicated to developing transformative first and best-in-class antibody-drug conjugate therapies for cancers | Directeur/Membre du Conseil | - |
Oxford Science Enterprises PLC
 Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises invests in companies located in the United Kingdom. The firm targets companies operating in the fields of health tech, deep tech, and life sciences sectors. It provides financing for seed and early stage capital requirements with an investment size of GBP 0.1 – 10 million. | Private Equity Investor | 01/02/2023 |
Anciens postes connus de Sanne de Jongh
| Sociétés | Poste | Fin |
|---|---|---|
Anterra Capital BV
 Anterra Capital BV Investment ManagersFinance Anterra Capital invests in startups located in Europe and North America. The firm focuses on the food and agriculture sectors. It participates in early, and later-stage capital transactions with an investment size of up to USD 20 million per company. It acquires a minority stake and takes a seat on the board of directors. | Analyste en capital-investissement | 01/09/2017 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
85
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Gilde Healthcare Partners BV
Gilde Healthcare Partners BV Investment ManagersFinance Gilde Healthcare Partners invests in lower middle market companies located in North America and Europe with an EBITDA of EUR 3 -20 million. The firm targets companies operating across a broad range of sectors and industries. It provides financing for seed, early, later, buyout and growth stage capital requirements with an investment size of EUR 50 million. It takes both minority and majority positions. | Finance |
Anterra Capital BV
Anterra Capital BV Investment ManagersFinance Anterra Capital invests in startups located in Europe and North America. The firm focuses on the food and agriculture sectors. It participates in early, and later-stage capital transactions with an investment size of up to USD 20 million per company. It acquires a minority stake and takes a seat on the board of directors. | Finance |
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises invests in companies located in the United Kingdom. The firm targets companies operating in the fields of health tech, deep tech, and life sciences sectors. It provides financing for seed and early stage capital requirements with an investment size of GBP 0.1 – 10 million. | Finance |
ADCendo ApS
ADCendo ApS BiotechnologyHealth Technology Operates as a clinical-stage biotech company that dedicated to developing transformative first and best-in-class antibody-drug conjugate therapies for cancers | Health Technology |
